NCT04238663View on ClinicalTrials.gov

Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

MB02 (Bevacizumab Biosimilar)

Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion

DRUG

EU approved Avastin®

Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion

DRUG

US licenced Avastin®

Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion

Trial Locations (1)

14050

Early Phase Clinical Unit (EPCU) PAREXEL International GmbH, Berlin

All Listed Sponsors
lead

mAbxience Research S.L.

INDUSTRY

NCT04238663 - Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers | Biotech Hunter | Biotech Hunter